Replies to post #163573 on Biotech Values

[umiak]

The company will seek the FDA’s nod for marketing Lymphoseek in other types of cancer such as prostate and lung – opening up a potential global market of 8.6 million solid tumors a year, compared with 310,000 U.S. cases yearly of just breast cancer and melanoma.

Half of that--4.3*$300= $1.3B. Could easily have a market cap of 3B.

Not even counting diagnostic potential for Alzheimer's. At any rate when LS expands useage approval and becomes standard of care CAH will charge more than $300. That may even prompt the buyout.